Non-small cell lung cancer · line 2 · Selpercatinib monotherapy (LIBRETTO-001) — RET fusion+ NSCLC

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-SELPERCATINIB-NSCLC`

ID	`IND-NSCLC-2L-RET-FUSION-SELPERCATINIB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-NSCLC`
Sources	`SRC-ESMO-NSCLC-METASTATIC-2024` `SRC-LIBRETTO001-DRILON-2020` `SRC-NCCN-NSCLC-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track for RET fusion-positive NSCLC any line. Pralsetinib alternative (separate future Indication).

Used By

Algorithms

ALGO-NSCLC-METASTATIC-2L - ALGO-NSCLC-METASTATIC-2L